Skip to content

Wednesday, October 28, 2026

Data from SEC filings, checked daily

Public filings, plainly told

About Method Sources Newsletter

Insider tradingForm 4

Cue Biopharma, Inc. (CUE) Insider Trading

7 open-market trades reported since Aug 14, 2026: 0 purchases worth $0 and 7 sales worth $2.43M.

By insider

Insider	Role	Buys	Bought	Sells	Sold	Latest
Shao-Lee Lin	CEO	0	$0	3	$1.91M	Oct 14, 2026
Sumita Ray	General Counsel	0	$0	2	$317K	Oct 14, 2026
Michael Vincent Meluzio	VP	0	$0	2	$201K	Oct 14, 2026

All trades

CUE insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	3 mo. after	Filing
Oct 14	Oct 12	Shao-Lee LinCEO	CEO	▼ SELL	11,087	27.55	$305K	−1.6%		Form 4 ↗
Oct 14	Oct 12	Sumita RayGeneral Counsel	General Counsel	▼ SELL	1,844	28.05	$52K	−1.6%		Form 4 ↗
Oct 14	Oct 12	Michael Vincent MeluzioVP	VP	▼ SELL	1,144	28.05	$32K	−2.3%		Form 4 ↗
Aug 17	Aug 13	Sumita RayGeneral Counsel	General Counsel	▼ SELL	8,829	30.09	$266K	−6.9%		Form 4 ↗
Aug 17	Aug 13	Michael Vincent MeluzioVP	VP	▼ SELL	5,628	30.09	$169K	−10%		Form 4 ↗
Aug 14	Aug 12	Shao-Lee LinCEO	CEO	▼ SELL	40,000	27.10	$1.08M	−5.2%		Form 4 ↗
Aug 14	Aug 13	Shao-Lee LinCEO	CEO	▼ SELL	18,258	28.62	$523K	−2.5%		Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings